We are live on ! Find out more
DRMA icon

Dermata Therapeutics

6 hedge funds and large institutions have $1.19M invested in Dermata Therapeutics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more ownership

Funds ownership: 0%0% (+0%)

Holders
6
Holders Change
+6
Holders Change %
% of All Funds
0.11%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
Reduced
Closed
Calls
$786K
Puts
Net Calls
+$786K
Net Calls Change
+$786K
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
1
AIGH Capital Management
Maryland
$786K +$864K +73 New
WVP
2
Worth Venture Partners
New Jersey
$180K +$201K +17 New
VF
3
Virtu Financial
New York
$101K +$106K +9 New
Geode Capital Management
4
Geode Capital Management
Massachusetts
$71K +$82.8K +7 New
BlackRock
5
BlackRock
New York
$26K +$23.7K +2 New
TRCT
6
Tower Research Capital (TRC)
New York
$21K +$23.7K +2 New
UBS Group
7
UBS Group
Switzerland
$1K

DRMA Hedge Fund Activity: Q3 2021 in Review

6 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q3 2021, worth a combined $1.19M.

Buyers outnumbered sellers: 6 funds opened new DRMA positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was AIGH Capital Management, opening a new position worth an estimated $864K.

  • 6 institutional investors held Dermata Therapeutics (DRMA) as of Q3 2021, up from 0 in Q2 2021.
  • Funds reported $1.19M of Dermata Therapeutics stock for Q3 2021.
  • 6 funds opened new Dermata Therapeutics positions in Q3 2021 and 0 closed out, a net change of +6 holders.
  • The largest Dermata Therapeutics buyer in Q3 2021 was AIGH Capital Management, an estimated $864K added.

Based on aggregated 13F filings for Q3 2021.